Family · Pharmaceutical analytical standards
Lumateperone
An atypical antipsychotic acting on serotonin and dopamine receptors, approved in the United States in 2019 for schizophrenia, in 2021 for bipolar depression and in 2025 as an add-on treatment for major depression. This family brings together the active ingredient, metabolites, labelled standards, nitrosamines and other impurities.
Did you know?Chemically it is a butyrophenone, like the much older haloperidol, yet it binds dopamine D2 receptors far less: at the doses used it occupies only about 40% of them.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
